**Bain Capital Plans to Divest Stake in Emcure Pharmaceuticals**
Bain Capital, a global private equity firm, is set to divest its stake in Emcure Pharmaceuticals Ltd, a listed pharmaceutical manufacturer, through a significant block deal. This decision follows the expiration of the lock-in period for selling shares in the Pune-based company, which ended in February 2025. The firm is expected to sell a stake valued at over $200 million (approximately ₹1,700 crore) and has engaged Kotak Mahindra Capital Co. to facilitate the transaction.
### Stake Details and Market Performance
– As of December 2024, Bain Capital, through its investment vehicle BC Investments IV Ltd., held an 8.68% stake in Emcure, equating to around 16.5 million shares.
– Based on the closing stock price of ₹1,075 on March 31, 2025, this stake is valued at approximately ₹1,773.75 crore.
– Emcure Pharmaceuticals shares rose by 2.45% on the National Stock Exchange, with a total market capitalization of ₹20,363.92 crore.
– In contrast, the Nifty pharma index decreased by 0.65%, while the broader Nifty 50 index fell by 0.31%.
Bain Capital previously sold nearly a third of its 13.07% stake during Emcure’s listing. The firm acquired its stake in December 2013 for ₹700 crore from Blackstone Group, which had initially invested around $50 million in Emcure back in 2006.
### Emcure Pharmaceuticals Overview
Founded in 1981 by Satish Ramanlal Mehta, Emcure Pharmaceuticals was listed on Indian stock exchanges on July 10, 2024, with shares debuting at ₹1,325.05, reflecting a 31.45% premium over the issue price of ₹1,008. The company specializes in developing and manufacturing a wide range of pharmaceutical products across various therapeutic areas.
**FAQ: What is Bain Capital’s plan for its investment in Emcure Pharmaceuticals?**
Bain Capital plans to divest its stake in Emcure Pharmaceuticals through a block deal, potentially selling over $200 million worth of shares following the end of the lock-in period.
